The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu, MD, Jefferson Health, Sidney Kimmel Cancer Center, Philadelphia, PA, gives an overview of the current standard of care (SOC) in cutaneous T-cell lymphoma (CTCL), which depends on the stage of an individual’s disease. Dr Porcu first discusses various types of skin-directed therapy, and then comments on the challenges of treating patients with early stage disease who fail skin-directed therapies. To conclude, Dr Porcu summarizes various forms of systemic therapy used in CTCL, including retinoids, methotrexate, HDAC inhibitors, and novel immunotherapeutic agents being explored. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
